Associated Papers
Secondary Resistant Mutations to Small Molecule Inhibitors in Cancer Cells.
Hamid AB et al.
Cancers, 2020
The Immunogenic Potential of Recurrent Cancer Drug Resistance Mutations: An In Silico Study.
Punta M et al.
Frontiers in Immunology, 2020
33133066 (PubMed )
Supplement: Table_1.xlsx › Resistance-no-BCR-ABL1
Integrative omics analyses broaden treatment targets in human cancer.
Sengupta S et al.
Genome Medicine, 2018
30053901 (PubMed )
Supplement: 13073_2018_564_MOESM2_ESM.xlsx › 3
Activated MEK cooperates with Cdkn2a and Pten loss to promote the development and maintenance of melanoma.
Yang H et al.
Oncogene, 2017
The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma.
Van Allen EM et al.
Cancer Discovery, 2014
Select a paper to view details